NEW YORK, Oct. 20 (GenomeWeb News) - Icoria has received a Small Business Innovation Research contract worth around $800,000 from the National Institute on Alcohol Abuse and Alcoholism $800,000.
The Phase II contract will help pay for Icoria's metabolomics and gene expression-analysis research of alcohol-related diseases, including liver and brain injury, according to the company. The study is called "Metabolomics: Alcohol Induced Toxicity."
The contract is the second Phase II SBIR contract Icoria has received. The company received a $1.2 million contract this summer. "Together, the two Phase II SBIR contracts help to support our biomarker discovery efforts on a broad set of liver pathologies that span a variety of mechanisms," Thomas Colatsky, Icoria's CSO, said in a statement today.
"By using metabolomics and gene expression to analyze different forms of liver toxicity, we hope to identify new biomarkers for liver disease that should have utility in the development of highly-informative, minimally invasive diagnostics covering acute as well as more chronic liver-related diseases, including alcoholic and non-alcoholic fatty liver disease."